Immunic Publishes Phase 1/1b Trial Data of IMU-856 in The Lancet

Immunic, Inc. has announced the publication of its Phase 1/1b clinical trial data for IMU-856 in The Lancet Gastroenterology & Hepatology. The trial results involve healthy individuals and patients with celiac disease, highlighting IMU-856’s potential as a small molecule modulator targeting SIRT6. This approach aims to improve intestinal barrier function, offering a new potential treatment for celiac disease.

The Phase 1b trial data showed that IMU-856 could mitigate gluten-related effects in celiac patients, improving symptoms and biomarkers compared to placebo, while maintaining a favorable safety profile. The study underscores the potential of IMU-856 to serve as an oral therapy for celiac disease and possibly other gastrointestinal conditions.

A total of 43 celiac disease patients participated in the double-blind, placebo-controlled trial, where IMU-856 demonstrated significant improvements in gut architecture and nutrient absorption over a 28-day period. The results advocate further exploration in a Phase 2 trial.